A role for corticotropin-releasing factor in functional gastrointestinal disorders

Current Gastroenterology Reports

Volumn 11, Issue 4, 2009, Pages 270-277

  Taché, Yvette ^a   Kiank, Cornelia ^a   Stengel, Andreas ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; BMS 562086; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CP 154 526; CP 316311; NBI 30075; NBI 34041; PLACEBO; UNCLASSIFIED DRUG; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY DISORDER; AUTONOMIC DYSFUNCTION; BACTERIAL TRANSLOCATION; CELL ACTIVATION; CLINICAL FEATURE; CLINICAL TRIAL; COLON MOTILITY; COMORBIDITY; CORTICOTROPIN RELEASE; DEPRESSION; DIARRHEA; DRUG EFFICACY; HUMAN; HYPERALGESIA; HYPERVIGILANT BEHAVIOR; HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LIGAND BINDING; MAST CELL; MENTAL STRESS; MUCUS SECRETION; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; VISCERAL PAIN;

ANIMALS; ANXIETY; DEPRESSION; DISEASE MODELS, ANIMAL; GASTROINTESTINAL DISEASES; HUMANS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RISK FACTORS; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 67849089070     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0040-4     Document Type: Review

References (62)

1. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006, 130: 1377-1390.
2. Talley NJ: Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 2008, 20(Suppl 1): 121-129.
3. Mayer EA: The challenge of studying the biology of complex, symptom-based GI disorders. Gastroenterology 2008, 134: 1826-1827.
4. Limsui D, Pardi DS, Camilleri M, et al.: Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007, 13: 175-181.
5. Kindt S, Van Oudenhove L, Broekaert D, et al.: Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009, 21: 389-398.
6. Grover M, Drossman DA: Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol 2008, 8: 715-723.
7. Taché Y, Bonaz B: Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest 2007, 117: 33-40.
8. Gareau MG, Silva MA, Perdue MH: Pathophysiological mechanisms of stress-induced intestinal damage. Curr Mol Med 2008, 8: 274-281.
9. Grover M, Herfarth H, Drossman DA: The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 2009, 7: 48-53.
10. Riedl A, Schmidtmann M, Stengel A, et al.: Somatic comorbidities of irritable bowel syndrome: A systematic analysis. J Psychosom Res 2008, 64: 573-582.
11. Bale TL: SensitivDty to stress: dysregulation of CRF pathways and disease development. Horm Behav 2005, 48: 1-10.
12. Fukudo S: Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol 2007, 42(Suppl 17): 48-51.
13. Bale TL, Vale WWR CRF and CRF receptor: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004, 44: 525-557.
14. Wood SK, Woods JH: Corticotropin-releAsing factor receptor-1: a therapeutic target for cardiac autonomic disturbances. Expert Opin Ther Targets 2007, 11: 1401-1413.
15. Hauger RL, Grigoriadis DE, Dallman MF, et al.: International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 2003, 55: 21-26.
16. Fekete EM, Zorrilla EP: Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: Ancient CRF paralogs. Front Neuroendocrinol 2007, 28: 1-27.
17. Hillhouse EW, Grammatopoulos DK: The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: Implications for physiology and pathophysiology. Endocr Rev 2006, 27: 260-286.
18. Wu SV, Yuan P-Q, Wang L, et al.: Identification and characterization of multiple corticotropin-releasing factor type 2 receptor isoforms in the rat esophagus. Endocrinology 2007, 148: 1675-1687.
19. Markovic D, Lehnert H, Levine MA, Grammatopoulos DK: Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: Lessons from the receptor variant R1d. Mol Endocrinol 2008, 22: 2505-2519.
20. Chen AM, Perrin MH, Digruccio MR, et al.: A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci U S A 2005, 102: 2620-2625.
21. Wallon C, Yang PC, Keita AV, et al.: Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut 2008, 57: 50-58.
22. Kimura T, Amano T, Uehara H, et al.: Urocortin I is present in the enteric nervous system and exerts an excitatory effect via cholinergic and serotonergic pathways in the rat colon. Am J Physiol Gastrointest Liver Physiol 2007, 293: G903-G910.
23. Yuan PQ, Million M, Wu SV, et al.: Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats. Neurogastroenterol Motil 2007, 19: 923-936.
24. Silberstein S, Vogl AM, Bonfiglio JJ, et al.: Immunology, signal transduction, and behavior in hypothalamic-pituitary-adrenal axis-related genetic mouse models. Ann N Y Acad Sci 2009, 1153: 120-130.
25. Tayama J, Sagami Y, Shimada Y, et al.: Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterol Mot 2007, 19: 471-483.
26. Tellew JE, Luo Z: Small molecule antagonists of the corticotropin releasing factor (CRF) receptor: Recent medicinal chemistry developments. Curr Top Med Chem 2008, 8: 506-520.
27. Holsboer F, Ising M: Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008, 583: 350-357.
28. Trimble N, Johnson AC, Foster A, Greenwood-Van Meerveld B: Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. Neurogastroenterol Motil 2007, 19: 754-760.
29. Keck ME, Ohl F, HolsAoer F, Muller MB: Listening to mutant mice: a spotlight on the role of CRF/CRF receptor systems in affective disorders. Neurosci Biobehav Rev 2005, 29: 867-889.
30. Stahl SM, Wise DD: The potential role of a corticotrophin-releasing factor receptor-1 antagonist in psychiatric disorders. CNS Spectr 2008, 13: 467-483.
31. Taché Y, Brunnhuber S: From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: Implication in stress-related functional bowel diseases. Ann N Y Acad Sci 2008, 1148: 29-41.
32. Rivier J, Gulyas J, Kirby D, et al.: Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 2002, 45: 4737-4747.
33. Nazarloo HP, Buttrick PM, Saadat H, Dunn AJ: The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system. Curr Protein Pept Sci 2006, 7: 229-239.
34. Stengel A, Taché Y: Neuroendocrine control of the gut during stress: Corticotropin-releasing factor signaling pathways in the spotlight. Annu Rev Physiol 2009, 71: 219-239.
35. Fujii Y, Nomura S: A prospective study of the psychobehavioral factors responsible for a change from non-patient irritable bowel syndrome to IBS patient status. Biopsychosoc Med 2008, 2: 16.
36. Dinan TG, Quigley EM, Ahmed SM, et al.: Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker? Gastroenterology 2006, 130: 304-311.
37. Ising M, Zimmermann US, Kunzel HE, et al.: High-affinity CRF1 receptor antagonist NBI-34041: Preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007, 32: 1941-1949.
38. North CS, Hong BA, Alpers DH: Relationship of functional gastrointestinal disorders and psychiatric disorders: Implications for treatment. World J Gastroenterol 2007, 13: 2020-2027.
39. Ising M, Holsboer F: CRH-sub-1 receptor antagonists for the treatment of depression and anxiety. Exp Clin Psychopharmacol 2007, 15: 519-528.
40. Binneman B, Feltner D, Kolluri S, et al.: A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 2008, 165: 617-620.
41. Holsboer F, Barden N: Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996, 17: 187-205.
42. Tillisch K, Mayer EA, Labus JS, et al.: Sex specific alterations in autonomic function among patients with irritable bowel syndrome. Gut 2005, 54: 1396-1401.
43. Carney RM, Freedland KE, Veith RC: Depression, the autonomic nervous system, and coronary heart disease. Psychosom Med 2005, 67(Suppl 1): S29-S33.
44. Larauche M, Gourcerol G, Wang L, et al.: Cortagine, a CRF1 agonist, induces stress-like alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol 2009 (Epub ahead of print).
45. Nakade Y, Fukuda H, Iwa M, et al.: Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am J Physiol Gastrointest Liver Physiol 2007, 292: G1037-G1044.
46. Sagami Y, Shimada Y, Tayama J, et al.: Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004, 53: 958-964.
47. Sweetser S, Camilleri M, Linker Nord SJ, et al.: Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in females with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 2009 (Epub ahead of print).
48. Martinez V, Taché Y: CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 2006, 12: 1-18.
49. Larauche M, Bradesi S, Million M, et al.: Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol 2008, 294: G1033-G1040.
50. Saito-Nakaya K, Hasegawa R, Nagura Y, et al.: Corticotropin-releasing hormone receptor 1 antagonist blocks colonic hypersensitivity induced by a combination of inflammation and repetitive colorectal distension. Neurogastroenterol Motil 2008, 20: 1147-1156.
51. Nozu T, Kudaira M: Corticotropin-releasing factor induces rectal hypersensitivity after repetitive painful rectal distention in healthy humans. J Gastroenterol 2006, 41: 740-744.
52. Naliboff BD, Berman S, Suyenobu B, et al.: Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients. Gastroenterology 2006, 131: 352-365.
53. Kosoyan H, Grigoriadis D, Taché Y: The CRF1 antagonist, NBI-35965 abolished the activation of locus coeruleus by colorectal distention and intracisternal CRF in rats. Brain Res 2005, 1056: 85-96.
54. Camilleri M, Gorman H: Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007, 19: 545-552.
55. Piche T, Barbara G, Aubert P, et al.: Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009, 58: 196-201.
56. Teitelbaum AA, Gareau MG, Jury J, et al.: Chronic peripheral administration of corticotropin-releasing factor causes colonic barrier dysfunction similar to psychological stress. Am J Physiol Gastrointest Liver Physiol 2008, 295: G452-G459.
57. Santos J, Yates D, Guilarte M, et al.: Stress neuropeptides evoke epithelial responses via mast cell activation in the rat colon. Psychoneuroendocrinology 2008, 33: 1248-1256.
58. De Giorgio R, Barbara G: Is irritable bowel syndrome an inflammatory disorder? Curr Gastroenterol Rep 2008, 10: 385-390.
59. Santos J, Alonso C, Vicario M, et al.: Neuropharmacology of stress-induced mucosal inflammation: Implications for inflammatory bowel disease and irritable bowel syndrome. Curr Mol Med 2008, 8: 258-273.
60. Posserud I, Stotzer PO, Bjornsson ES, et al.: Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007, 56: 802-808.
61. Liebregts T, Adam B, Bredack C, et al.: Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007, 132: 913-920.
62. Gross KJ, Pothoulakis C: Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007, 13: 918-932.